AR026647A1 - Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas - Google Patents

Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas

Info

Publication number
AR026647A1
AR026647A1 ARP000106286A ARP000106286A AR026647A1 AR 026647 A1 AR026647 A1 AR 026647A1 AR P000106286 A ARP000106286 A AR P000106286A AR P000106286 A ARP000106286 A AR P000106286A AR 026647 A1 AR026647 A1 AR 026647A1
Authority
AR
Argentina
Prior art keywords
core
elastomer
pharmacos
supply
drug
Prior art date
Application number
ARP000106286A
Other languages
English (en)
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of AR026647A1 publication Critical patent/AR026647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
    • C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C08G77/18—Polysiloxanes containing silicon bound to oxygen-containing groups to alkoxy or aryloxy groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/44—Block-or graft-polymers containing polysiloxane sequences containing only polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/48—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
    • C08G77/50—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Polymers & Plastics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

La invencion se refiere a un dispositivo para la liberacion controlada durante un período de tiempo prolongado, de un fármaco que tiene propiedadesantiprogestínicas, comprendiendo dicho dispositivo, un nucleo que comprende dicho fármaco, opcionalment e una membrana que encierra dicho nucleo, en el quedicho nucleo y/o membrana están hechos de una composicion elastomero basado en siloxano que comprende al menos un elastomero y posiblemente un polímero noentrecruzado. El dispositivo está caracteriza do porque la composicion de elastomero comprende grupos poli(oxido de alquileno) y porque los grupos poli(oxido dealquileno) están presentes en el elastomero o polímero como injertos terminados con alcoxi de unidades de polisiloxano, o como bloques, estando unidos dichosinjertos o bloques a las unidades de polisiloxano por enlaces silicio-carbono o como mezcla de estas formas.
ARP000106286A 1999-12-23 2000-11-29 Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas AR026647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/472,126 US6476079B1 (en) 1999-12-23 1999-12-23 Devices for the delivery of drugs having antiprogestinic properties

Publications (1)

Publication Number Publication Date
AR026647A1 true AR026647A1 (es) 2003-02-19

Family

ID=23874296

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106286A AR026647A1 (es) 1999-12-23 2000-11-29 Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas

Country Status (31)

Country Link
US (1) US6476079B1 (es)
EP (1) EP1239829B1 (es)
JP (1) JP4895150B2 (es)
KR (1) KR100850548B1 (es)
CN (1) CN100346772C (es)
AR (1) AR026647A1 (es)
AT (1) ATE401859T1 (es)
AU (1) AU781555B2 (es)
BR (1) BR0016697A (es)
CA (1) CA2395226C (es)
CO (1) CO5261571A1 (es)
CZ (1) CZ301865B6 (es)
DE (2) DE60039626D1 (es)
DK (1) DK1239829T3 (es)
EE (1) EE05123B1 (es)
ES (1) ES2310526T3 (es)
HK (1) HK1047235B (es)
HU (1) HU229438B1 (es)
IL (2) IL149663A0 (es)
MX (1) MXPA02006174A (es)
NO (1) NO332261B1 (es)
NZ (1) NZ519876A (es)
PE (1) PE20010801A1 (es)
PL (1) PL201216B1 (es)
PT (1) PT1239829E (es)
RU (1) RU2228170C2 (es)
SK (1) SK287229B6 (es)
TW (1) TWI248367B (es)
UA (1) UA70401C2 (es)
WO (1) WO2001047490A1 (es)
ZA (1) ZA200203620B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887948B2 (en) * 1998-06-30 2005-05-03 Schering Oy Method for preparing a siloxane-based elastomer composition
US6794464B2 (en) 1998-06-30 2004-09-21 Schering Oy Membrane or matrix for controlling the permeation rate of drugs
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
CN1289064C (zh) * 2001-08-31 2006-12-13 先灵有限责任公司 药物输送体系
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
WO2005051234A2 (en) * 2003-11-13 2005-06-09 Control Delivery Systems, Inc. Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
KR101420988B1 (ko) 2005-10-13 2014-07-17 신세스 게엠바하 약물-함침 용기
US20070149916A1 (en) * 2005-12-22 2007-06-28 Alza Corporation Dry matrices as drug reservoirs in electrotransport applications
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
EP2057972A1 (en) * 2007-11-07 2009-05-13 N.V. Organon Intrauterine deposit
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2349143B2 (en) 2008-09-17 2016-08-10 Bayer Oy An inserter
US11992431B2 (en) 2008-09-17 2024-05-28 Bayer Oy Inserter
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
WO2010052275A2 (en) * 2008-11-06 2010-05-14 Novo Nordisk A/S Electronically assisted drug delivery device
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8568374B2 (en) * 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
JP5894143B2 (ja) * 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
WO2014121188A1 (en) 2013-02-04 2014-08-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
MX357598B (es) * 2011-07-20 2018-07-16 F Kiser Patrick Dispositivos intravaginales para administración de fármaco.
TWI590843B (zh) 2011-12-28 2017-07-11 信迪思有限公司 膜及其製造方法
EP2890760A4 (en) 2012-08-30 2016-10-12 Atrp Solutions Inc DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
AU2014214538B2 (en) 2013-02-06 2018-11-15 Mark SILLENDER Embryo transfer catheter and method
EP2953678B1 (en) 2013-02-06 2020-03-25 Sillender, Mark Therapeutic substance transfer catheter
US9352049B2 (en) 2013-03-14 2016-05-31 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
EP2983671B1 (en) 2013-04-11 2018-10-24 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
BR112015032045B1 (pt) 2013-06-21 2020-06-09 Depuy Synthes Products Inc corpo flexível, método para formar um filme multicamadas para uso em combinação com um dispositivo médico implantável, sistema de armazenamento de filme e sistema para tratamento ortopédico
US10106818B2 (en) 2013-08-16 2018-10-23 The J. David Gladstone Institutes Dual-color HIV reporter system for the detection of latently-infected cells
HUE040176T2 (hu) * 2014-06-28 2019-02-28 Laboratorios Andromaco S A Elnyújtott, hosszantartó és folyamatos felszabadulású progeszteront tartalmazó méhnyakpesszárium koraszülés megelõzésére
JP6689210B2 (ja) 2014-07-03 2020-04-28 パイロット ポリマー テクノロジーズ， インク． 界面活性剤相溶性星形高分子
EP3206751A4 (en) 2014-10-14 2018-06-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
CN107406677A (zh) * 2015-03-05 2017-11-28 道康宁东丽株式会社 可固化有机聚硅氧烷组合物、其用途以及由该组合物制备的层合体
EP3294300A1 (en) * 2015-05-13 2018-03-21 Bayer Oy A long acting drug delivery device and its use in contraception
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
WO2020041333A1 (en) 2018-08-22 2020-02-27 The J. David Gladstone Institutes Methods for treating cardiac valve disease
US20220364119A1 (en) 2019-06-14 2022-11-17 The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
TWI803052B (zh) * 2021-11-12 2023-05-21 佛教慈濟醫療財團法人 經皮遞送裝置及其使用及製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
JPS519003B1 (es) * 1970-11-07 1976-03-23
US3836560A (en) 1971-03-08 1974-09-17 Union Carbide Corp Organosilicone polymers
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4323488A (en) * 1979-03-26 1982-04-06 Shin-Etsu Chemical Company Limited Method for the preparation of silicone-modified polyoxyalkylene polyethers and room temperature-curable compositions therewith
JPS60148560A (ja) * 1984-01-17 1985-08-05 富士システムズ株式会社 皮膚用封止材
CA1257727A (en) * 1984-12-18 1989-07-18 Chi-Long Lee Hydrophilic silicone-organic copolymer elastomers
US4600751A (en) * 1984-12-18 1986-07-15 Dow Corning Corporation Hydrophilic silicone-organic copolymer elastomers
GB8704755D0 (en) * 1987-02-28 1987-04-01 Dow Corning Ltd Pharmaceutical delivery device
US4951657A (en) * 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
EP0545002A1 (en) 1991-11-21 1993-06-09 Kose Corporation Silicone polymer, paste-like composition and water-in-oil type cosmetic composition comprising the same
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
JP3201940B2 (ja) * 1995-09-12 2001-08-27 信越化学工業株式会社 硬化性シリコーンエラストマー組成物及びその製造方法
US5811487A (en) * 1996-12-16 1998-09-22 Dow Corning Corporation Thickening silicones with elastomeric silicone polyethers
US5889108A (en) 1997-06-02 1999-03-30 Dow Corning Corporation Thickening solvents with elastomeric silicone polyethers
US6013711A (en) 1997-06-18 2000-01-11 Ck Witco Corporation Hydrophilic polysiloxane compositions
FI103051B (fi) 1997-08-22 1999-04-15 Schering Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens

Also Published As

Publication number Publication date
US6476079B1 (en) 2002-11-05
HU229438B1 (hu) 2013-12-30
CN100346772C (zh) 2007-11-07
EE200200349A (et) 2003-08-15
KR100850548B1 (ko) 2008-08-06
NO20023012L (no) 2002-08-09
TWI248367B (en) 2006-02-01
JP4895150B2 (ja) 2012-03-14
KR20020067573A (ko) 2002-08-22
NO332261B1 (no) 2012-08-13
CZ20022106A3 (cs) 2002-11-13
PL201216B1 (pl) 2009-03-31
EE05123B1 (et) 2009-02-16
PT1239829E (pt) 2008-10-09
DK1239829T3 (da) 2008-11-24
AU1710201A (en) 2001-07-09
EP1239829A1 (en) 2002-09-18
UA70401C2 (uk) 2004-10-15
NZ519876A (en) 2004-02-27
DE1239829T1 (de) 2003-02-06
PE20010801A1 (es) 2001-08-09
SK7012002A3 (en) 2003-01-09
WO2001047490A1 (en) 2001-07-05
ZA200203620B (en) 2003-07-30
BR0016697A (pt) 2002-09-03
EP1239829B1 (en) 2008-07-23
AU781555B2 (en) 2005-06-02
DE60039626D1 (de) 2008-09-04
JP2003518482A (ja) 2003-06-10
HUP0204015A2 (en) 2003-05-28
HK1047235A1 (en) 2003-02-14
HK1047235B (zh) 2009-04-24
CO5261571A1 (es) 2003-03-31
CA2395226A1 (en) 2001-07-05
IL149663A0 (en) 2002-11-10
ES2310526T3 (es) 2009-01-16
RU2002119587A (ru) 2004-02-27
CZ301865B6 (cs) 2010-07-14
CA2395226C (en) 2009-01-27
IL149663A (en) 2007-02-11
PL355994A1 (en) 2004-05-31
SK287229B6 (sk) 2010-03-08
ATE401859T1 (de) 2008-08-15
HUP0204015A3 (en) 2004-06-28
NO20023012D0 (no) 2002-06-21
RU2228170C2 (ru) 2004-05-10
CN1420762A (zh) 2003-05-28
MXPA02006174A (es) 2002-12-05

Similar Documents

Publication Publication Date Title
AR026647A1 (es) Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas
PE20030316A1 (es) Sistema de suministro de dos o mas agentes terapeuticamente activos
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
AR018952A1 (es) Una membrana o matriz para controlar la velocidad de penetracion de farmacos
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2140952T3 (es) Composiciones para el maquillaje de los ojos.
DK1343492T3 (da) Behandling af mucositis
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
BRPI0411071A (pt) sistemas de reticulação para polìmeros de hidroxila
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
CR8402A (es) Indazol-o-glucosidos sustitutos
AR030925A1 (es) Uso de un agente bacteriano y las composiciones cosmeticas, farmaceuticas o veterinarias que contienen dicho agente bacteriano
AR077759A2 (es) Anticuerpos bloqueadores de cripto composiciones que los comprenden y usos y metodos que los utilizan
DE60141972D1 (de) Hydrophile vernetzbare silikone
ES2166066T3 (es) Composiciones antimicrobianas sinergicas que contienen un polimero ioneno y una sal de dodecilamina y sus metodos de utilizacion.
ES2069686T3 (es) Reticulacion de prepolimeros de siloxano con funciones (met)acriloxialquenileno.
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
AR009089A1 (es) Composiciones para el cuidado del color que comprenden un agente fijador de colorante y un polimero y un metodo para proporcionar cuidado de color
PE20001365A1 (es) Dispositivo de suministro de farmacos, especialmente para el suministro de androgenos
GT200600130A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
BRPI0400290A (pt) Agente de liberação de fluorsilicone misto para membros de fusão de silicone

Legal Events

Date Code Title Description
FB Suspension of granting procedure